港股异动丨信达生物大涨超13% 24年收入达94.2亿元创新高 肿瘤品牌领跑市场

格隆汇
27 Mar

中国领先的生物制药公司信达生物(1801.HK)大幅上涨超13%,高见44.7港元刷新阶段新高,成交额明显放大至超12亿港元,总市值727.3亿港元。消息上,2024年公司全年总收入同比增长51.8%至人民币94.2亿元创新高,其中产品收入人民币82.3亿元,同比增长43.6%。收入强劲的增长势头得益于公司在中国肿瘤领域领先的品牌地位,达伯舒(信迪利单抗注射液)等主要产品持续保持良好的增长势头,新产品组合的快速增长贡献新动力。展望未来,2025年将是公司迈进双轮驱动和全球创新发展新时期的关键元年,将进一步解锁向上空间,朝着“成为国际一流的生物制药公司”的愿景稳步迈进。(格隆汇)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10